Evidence is mixed rather than simply “proven” or “disproven”
NCCIH summarizes 2022 reviews that reached inconsistent conclusions: some analyses found potential pain reduction in diabetic neuropathy while others found no clear benefit across included studies. Differences in design, participants, dose and outcomes make simple marketing summaries unreliable.
Safety data still does not create a universal recommendation
NCCIH notes common reported side effects such as headache, heartburn, nausea and vomiting. A product can have an acceptable safety profile in research and still be unsuitable for a particular person because of medications, conditions or dose.
Why this matters when reading NervoVive claims
The official NervoVive formula source used in this build does not list alpha-lipoic acid. More importantly, research on one ingredient cannot be transferred to a different multi-ingredient product. This is the core principle used on our NervoVive evidence review.
Sources used for this research page
NCCIH: Diabetes and Dietary Supplements
Federal evidence summary including alpha-lipoic acid and diabetic neuropathy research.